Cognition Therapeutics, Inc. (CGTX) Launches 3.35M Share IPO

Cognition Therapeutics, Inc (NASDAQ: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced that it has launched an initial public offering of 3,350,000 shares of its common stock. In addition, Cognition expects to grant the underwriters a 45-day option to purchase up to an additional 502,500 shares of its common stock at the public offering price, less the underwriting discount. All of the shares of common stock are being offered by Cognition. The initial public offering price is expected to be between $11.00 and $13.00 per share. Cognition’s common stock has been approved for listing on The Nasdaq Global Market under the symbol “CGTX.”

B. Riley Securities, Inc. is acting as the lead bookrunner; additionally, Oppenheimer & Co. is acting as a joint bookrunner. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

A registration statement related to the shares being sold in this offering has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

You May Also Be Interested In

• SpaceX shares gain as lock-up fears ease
• iSpecimen closes $5 million public offering of stock and warrants
• Nth Cycle files draft S-4 for SPAC merger at $585M enterprise value